Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-β signaling
Journal of Neuro-Oncology · 2025
DOI: 10.1007/s11060-025-05089-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Niket Yadav und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA, 22903, USA. Hauptthemen laut MEDLINE: Simvastatin, Irinotecan, Glioblastoma, Transforming Growth Factor beta. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Virginia Comprehensive Cancer Center, NIGMS NIH HHS, NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
This study investigates the synergistic therapeutic potential of a novel combination of the repurposed drug simvastatin with irinotecan chemotherapy towards glioblastoma (GBM) and the underlying molecular mechanisms.
Methods
In vitro efficacy of simvastatin and irinotecan alone and in combination against diverse GBM lines (U251MG, G34, SB28) was assessed using mechanistically distinct cell viability assays. RNA-Sequencing was performed to uncover the top pathways and genes affected by these drugs, followed by validation of promising pathways (TGF-β signaling and cell death) using targeted phosphoproteomics and in vitro genetic manipulation and functional assays.
Results
We observed robust in vitro synergy at nanomolar concentrations between simvastatin and irinotecan across diverse GBM lines. Notably, irinotecan alone and in combination with simvastatin reduced mRNA expression of TGF-β family members. Targeted phosphoproteomics and functional experiments further showed significant inhibition of TGF-β signaling with both treatment types. Additionally, a role for apoptosis and enrichment of caspase-independent cell death pathways (autophagy, ferroptosis) as well as immunological (interferons, complement, inflammatory responses, TNF-α) and oncogenic (K-RAS/ERK) signaling pathways were observed with the combination treatment.
Conclusions
Besides the first detailed demonstration of a robust synergy between simvastatin and irinotecan against GBM lines, this study shows for the first time that both irinotecan and the combination treatment converge on inhibition of TGF-β signaling. This is notable given the lack of TGF-β inhibitors in the clinic. Collectively, this study provides preclinical data suggesting this novel drug combination be tested in patients with GBM and TGF-β driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA, 22903, USA.
- Medical Scientist Training Program (MSTP), University of Virginia School of Medicine, Charlottesville, VA, 22903, USA.
- Molecular and Cellular Basis of Disease (MCBD) Graduate Program, Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, 22903, USA.
- Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, 22903, USA.
- Bioinformatics Core, University of Virginia, Charlottesville, VA, 22903, USA.
- Department of Chemical Engineering, University of Virginia, Charlottesville, VA, 22903, USA.
Förderung
- University of Virginia Comprehensive Cancer Center
- NIGMS NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Institute of General Medical Sciences
- National Cancer Institute
- Schiff Foundation
Zitieren
APA
Yadav, N., Xiao, A., Zhong, Q., Kumar, P., Konduru, G., Hart, W., Lazzara, M., & Purow, B. (2025). Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-β signaling. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-05089-8
Vancouver
Yadav N, Xiao A, Zhong Q, Kumar P, Konduru G, Hart W, et al. Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-β signaling. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-025-05089-8
BibTeX
@article{Yadav2025,
author = {Yadav, Niket and Xiao, Aizhen and Zhong, Qing and Kumar, Pankaj and Konduru, Guruprasad and Hart, William and Lazzara, Matthew and Purow, Benjamin},
title = {Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-β signaling},
journal = {Journal of Neuro-Oncology},
year = {2025},
doi = {10.1007/s11060-025-05089-8}
}
EUVIMED